Testosterone therapy with Testopel® and the Esoterix Laboratory assay: A CASE study.
Case report
Pharmacokinetics
Testosterone pellets
Testosterone replacement therapy
Journal
Urology case reports
ISSN: 2214-4420
Titre abrégé: Urol Case Rep
Pays: United States
ID NLM: 101626357
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
24
04
2021
accepted:
10
05
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
epublish
Résumé
We present a patient receiving Testopel® implants whose serum testosterone levels, as measured by a CDC certified assay, were accurately predicted by a multi-compartmental model. This is the first time a model has predicted measured serum testosterone levels within 4% of values calculated. To our knowledge, it was also the first time a pharmacokinetic model allowed patient targeted serum levels (peak/trough/average) to be reached within three months.
Identifiants
pubmed: 34094874
doi: 10.1016/j.eucr.2021.101714
pii: S2214-4420(21)00154-6
pmc: PMC8165545
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101714Informations de copyright
© 2021 Published by Elsevier Inc.
Références
Clin Endocrinol (Oxf). 2013 Feb;78(2):291-6
pubmed: 22804876